Nasdaq:US$15.69 (+0.28) | HKEX:HK$25.40 (+0.50) | AIM:£2.21 (-0.02)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2013-04-06

AACR 2013: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor -1, -2, and -3 tyrosine kinases in patients with advanced solid tumors